New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line

Angelika Długosz-Pokorska¹, Marlena Pięta², Jacek Kędzia², Tomasz Janecki² and Anna Janecka¹*

**Abstract**

**Background:** 5-Fluorouracil (5-FU) is an antimetabolite that interferes with DNA synthesis and has been widely used as a chemotherapeutic drug in various types of cancers. However, the development of drug resistance greatly limits its application. Overexpression of ATP-binding cassette (ABC) transporters in many types of cancer is responsible for the reduction of the cellular uptake of various anticancer drugs causing multidrug resistance (MDR), the major obstacle in cancer chemotherapy. Recently, we have obtained a novel synthetic 5-FU analog, U-332 \([\text{exo}-3-(4-	ext{bromophenyl})-1-	ext{ethyl}-5-	ext{methylidene-6-phenyldihydrouracil}]\), combining a uracil skeleton with an exo-cyclic methylidene group. U-332 was highly cytotoxic for HL-60 cells and showed similar cytotoxicity in the 5-FU resistant subclone (HL-60/5FU), in which this analog almost completely abolished expression of the ATP-binding cassette (ABC) transporter, multidrug resistance associate protein 1 (ABCC1). The expression of ABC transporters is usually correlated with NF-κB activation. The aim of this study was to determine the level of NF-κB subunits in the resistant HL-60/5-FU cells and to evaluate the potential of U-332 to inhibit activation of NF-κB family members in this cell line.

**Methods:** Anti-proliferative activity of compound U-332 was assessed by the MTT assay. In order to disclose the mechanism of U-332 cytotoxicity, quantitative real-time PCR analysis of the NF-κB family genes, c-Rel, RelA, RelB, NF-κB1, and NF-κB2, was investigated. The ability of U-332 to reduce the activity of NF-κB members was studied by ELISA test.

**Results:** In this report it was demonstrated, using RT-PCR and ELISA assay, that members of the NF-κB family c-Rel, RelA, RelB, NF-κB1, and NF-κB2 were all overexpressed in the 5-FU-resistant HL-60/5FU cells and that U-332 potently reduced the activity of c-Rel, RelA and NF-κB1 subunits in this cell line.

**Conclusions:** This finding indicates that c-Rel, RelA and NF-κB1 subunits are responsible for the resistance of HL-60/5FU cells to 5-FU and that U-332 is able to reverse this resistance. U-332 can be viewed as an important lead compound in the search for novel drug candidates that would not cause multidrug resistance in cancer cells.

**Keywords:** Multidrug resistance, NF-κB subunits, Real-time PCR, ELISA assay, Uracil analog U-332
Background
The incidence of acute myeloid leukemia (AML) and heterogeneous clonal disorders of hematopoietic progenitor cells are increasing worldwide [1]. There are several therapies which are offered for patients with AML but survival after relapse remains poor, necessitating the search for novel chemotherapeutic candidates. At present, the toxic effect of chemotherapy and the occurrence of secondary malignancies associated with AML are the major drawbacks in the pharmacotherapy of AML. Moreover, the frequent acquisition of multidrug resistance (MDR) phenotype is the additional serious problem in the treatment of AML patients. Neoplastic cells are able to develop many different mechanisms of MDR, such as DNA mutations, cell metabolic changes and very often, overexpression of ATP-binding cassette (ABC) transporters and activation of the nuclear factor κB (NF-κB) [2–4].

5-Fluorouracil (5-FU) was the first synthetic fluoropyrimidine analog that showed pharmacological activity. At the molecular level, 5-FU is an antineoplastic antimetabolite that interferes with DNA synthesis by blocking the thymidylate synthase-catalyzed conversion of deoxyuridylic acid to thymidylic acid [5]. In numerous cancer cells, 5-FU induces apoptosis and cell cycle arrest and inhibits proliferation [6–8]. Since its first synthesis in 1957 [9] 5-FU has been widely used as a chemotherapeutic drug in various types of cancer [10]. However, its application is now limited due to the serious side-effects and the development of resistance [11]. Numerous modifications of 5-FU have been proposed so far, and new analogs modified at position 1, such as tegafur, carmofur and floxuridine (Fig. 1) are now replacing 5-FU in clinical practice [12].

Though new anticancer agents continue to be discovered, the problem of resistance is still a major
obstacle in obtaining efficient drug candidates. Among various mechanisms that can be developed by neoplastic cells in order to escape medical intervention, overexpression of ATP-binding cassette (ABC) transporters is the one well documented [3, 4]. The ABC transporter family are transmembrane proteins involved in the normal physiological process but also in the mechanism of drug resistance in cancer cells. The ABC proteins function as efflux pumps that can transport drugs out of the cells in the ATP energy-dependent mechanism, reducing their intracellular concentration [13]. The best known transporters that were shown to reduce the cellular uptake of anticancer drugs, including 5-FU, are P-glycoprotein (ABCB1), multidrug resistance associate protein 1 (ABCC1) and breast cancer resistance protein (ABCG2) [14–20].

The mechanism of ABC transporter regulation is still not fully understood. Recently, many transcription factor-binding sequences, such as those for p53, AP-1 and, very often, for NF-κB have been identified in the promoter region of the ABCB1 gene [21–23].

NF-κB consists of a family of five proteins, p65 (RelA), RelB, c-Rel, p105/p50 (NF-κB1), and p100/52 (NF-κB2) that may form different transcriptionally active homo- and heterodimeric complexes [24] (Fig. 2). The most important subunit of the NF-κB family is RelA/p65, which is phosphorylated in the posttranslational activation mechanism [24, 25]. RelB is the only NF-κB subunit that does not form homodimers and can trigger a potent transcriptional activation only when coupled to p50 or p52. The c-Rel plays an essential role in the regulation of T-cell-mediated immunity [26]. NF-κB1 and NF-κB2 are the precursor forms of p50 and p52, respectively [27].

---

**Fig. 2** The members of NF-κB family. The Rel homology domain is characteristic for all members the NF-κB family, while the ankyrin repeats only for the NF-κB inhibitors and the NF-κB precursors of p50 and p52 subunits (p100, p105). The transactivation domain is a C-terminal non-homologous domain that is important for NF-κB-mediated gene transactivation. For activation of transactivation domain, RelB requires an amino-terminal leucine zipper region.
Various chemotherapeutic drugs, including 5-FU, were shown to activate NF-κB. The members of the NF-κB family can be activated in several ways. In the classical NF-κB pathway, various cellular receptors, such as tumor necrosis factor receptors (TNFRs), are activated. Then, the inhibitory IκB proteins, that form dimers with NF-κB subunits, are phosphorylated at two specific serine residues. The IκB activation leads to disintegration of the NF-κB complexes. RelA- and c-Rel-containing dimers translocate to the nucleus where they regulate over 100 transcription targets. The genes whose expression is regulated by NF-κB play an important role in immune/stress responses, apoptosis, proliferation, differentiation and development [28, 29].

Continuing the search for novel compounds with anticancer properties, we have recently described a series of uracil analogs, combining uracil skeleton with an exo-cyclic methyldiene group conjugated with a carbonyl function [30]. These analogs were all highly cytotoxic against leukemia HL-60 cell line. The most potent analog of the series, (R)-3-(4-bromophenyl)-1-ethyl-5-methyldiene-6-phenyldihydrouracil, designated U-332 (Fig. 1), caused in HL-60 cells excessive DNA damage which led to the cell cycle arrest in G2/M phase and apoptosis. To determine the activity of U-332 in the resistant cells, we recently selected a 5-FU resistant subclone (HL-60/5FU) of HL-60 cell line by the conventional method of the continuous exposure of the cells to 5-FU up to 0.08 mmol/L concentration [31]. HL-60/5FU cells exhibited a 6-fold enhanced resistance to 5-FU as compared with HL-60 cells. RT-PCR and ELISA assay exhibited a 6-fold enhanced resistance to 5-FU as compared with HL-60 cells. The detailed description of this procedure was given elsewhere [31].

The aim of this study was to determine the level of NF-κB subunits in the resistant HL-60/5-FU cell line and to evaluate the potential of a novel uracil analog U-332 to inhibit activation of NF-κB family members in this cell line. For comparison, bengamide (BGD) [32], a potent inhibitor of NF-κB activation was included in the research.

Methods
Chemistry
Synthesis of (R)-3-(4-bromophenyl)-1-ethyl-5-methyldiene-6-phenyldihydrouracil (U-332) was performed using Horner-Wadsworth-Emmons methodology, as described elsewhere [33]. Starting 3-(4-bromophenyl)-5-diethoxyphosphoryl-1-ethyluracil I was transformed into 3-(4-bromophenyl)-5-dichlorophosphoryl-1-ethyluracil 2 which was next reacted with (R)-1-phenylethylamine to yield (R,R)-3-(4-bromophenyl)-5-di-(1-phenylethylamino)phosphoryl-1-ethyluracil (R,R)-3. This compound was used as a Michael acceptor in the reaction with phenylmagnesium chloride and obtained trans-adduct (R,R)-4 was separated and purified. Absolute configuration of this compound was confirmed by single crystal X-ray technique. When (R,R)-4 was applied in Horner-Wadsworth-Emmons olefination of formaldehyde, (R)-3-(4-bromophenyl)-1-ethyl-5-methyldiene-6-phenyldihydrouracil U-332 was obtained as pure enantiomer (ee > 99%).

Materials
BGD was obtained from Tocris Bioscience (Bristol, UK). U-332 and BGD were dissolved in DMSO and diluted in culture medium to obtain less than 0.1% DMSO v/v concentration.

Cell culture
The human leukemia cell line, HL-60 was purchased from the European Collection of Authenticated Cell Cultures (ECACC) and was cultured in RPMI 1640 plus GlutaMax I medium (Invitrogen, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS) and antibiotics (100 μg/mL streptomycin and 100 U/mL penicillin).

5-FU-resistant HL-60 cell line was obtained by a long-time exposure of HL-60 cells to increasing 5-FU concentrations (0.01–10 mg/L). The process was repeated until the cells were able to tolerate up to 10 mg/L of 5-FU. The detailed description of this procedure was given elsewhere [31].

Metabolic activity - MTT assay
The determination of anti-proliferative activity of U-332 and BGD was performed by the MTT assay, according to the Mosmann method, as described elsewhere [34].

Quantitative real-time PCR assay
The expression of NF-κB genes was analyzed by real-time PCR (RT-PCR). Briefly, the HL-60 and HL-60/5FU cells were seeded on the 6-well plates at the optimal cell density (3.0 × 10^5 cells/well in 3 mL of culture media), treated with the tested compounds at IC_{50} concentration each and left to grow for 24 h. Total RNA was directly extracted from cultured cells, using the Total RNA Mini Kit (A&A Biotechnology, Gdynia, Poland) while Transcripta Kit (A&A Biotechnology, Gdynia, Poland) was used for cDNA synthesis, according to the manufacturer’s procedure.

Amplification of cDNA was performed using Real-Time 2x-PCR SYBR Master Mix (A&A Biotechnology, Gdynia, Poland) and gene specific primers (RelA, RelB, etc.)
NF-κB1, NF-κB2 and c-Rel) (Table 1) in Stratagene MX3005P QPCR System (Agilent Technologies, Inc. Santa Clara, CA, USA) according to the manufacturer’s protocol. The housekeeping gene, GAPDH, was used as an internal reference gene for normalization of qPCR results. The gene expression levels were determined by the 2-ΔΔCT method [35].

Determination of NF-κB subunit activity by ELISA-based method
The activity of NF-κB family members (p50, p52, p65, c-Rel, RelB) was analyzed in the cellular protein extracts (10 μg) by the ELISA-based method using NF-κB (p50, p52, p65, c-Rel, RelB) Transcription Factor Assay Kit (ABCAM). Briefly, HL-60 and HL-60/5FU cells were seeded in triplicate into 6-well plates at the optimal cell density (4.5 × 10^5 cells/well in 3 mL of culture media). Then, U-332 and BGD at IC_{50} concentration each were added and cells were left to grow for 24 h. After incubation, cells were washed 3x in PBS and immediately collected by centrifugation (200×g, 5 min).

The Nuclear Extraction Kit was used in the preparation of nuclear extracts which were then analyzed using NF-κB oligonucleotide for NF-κB subunit binding site (5′-GGGACTTTCC-3′). Active NF-κB heterodimers present in the whole-cell extracts appropriately bind to this oligonucleotide.

For detection of p50, p52, p65, c-Rel or RelB, the primary antibodies recognizing an epitope on these NF-κB subunits were used. The secondary antibodies conjugated to horseradish peroxidase (HRP) provided sensitive colorimetric readout at OD 450 nm. The data were visualized using Flexstation 3.

Statistical analysis
Statistical analyses and all graphs were prepared using Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA). All data are presented as mean ± SEM. Statistical significance was assessed using one-way ANOVA followed by a post-hoc multiple comparison Student-Newman-Keuls test (for comparisons of three or more groups) or Student’s t-test (for comparisons of two groups). *p < 0.05, **p < 0.01, and ***p < 0.001, ****p < 0.0001 were considered significant.

Results

MTT-cell viability test
Cytotoxic activity of U-332 and BGD was examined using the MTT test. HL-60 and HL-60/5FU cells were exposed to a broad range of compound concentrations for 24 h (Fig. 3). BGD showed only a week cytotoxic effect (IC_{50} = 51 μM and 98 μM in HL-60 and HL60/5FU, respectively), while U-332 was 66- and 110-fold more cytotoxic (IC_{50} = 1.2 μM and 0.9 μM in HL-60 and HL60/5FU, respectively).

Expression level of NF-κB subunit genes
Analysis of the expression level of c-Rel, RelA, RelB, NF-κB1 (p100/p50) and NF-κB2 (p100/p52) genes in the HL-60 and resistant HL-60/5FU cells was performed by real-time PCR. In the HL-60/5FU cells, relative RelA, RelB, NF-κB1, NF-κB2 and c-Rel mRNA expression levels were 1.1-4.4-fold higher than in the parental HL-60 cells (Table 2).

Then, both types of cells were treated for 24 h with U-332 or BGD (at IC_{50} concentration each). In HL-60 cells, U-332 down-regulated the expression level of c-Rel, RelA, NF-κB1 and NF-κB2 genes, but the most pronounced effect (3.7-fold) was observed for NF-κB2 (Fig. 4a). A potent NF-κB inhibitor, BGD did not influence NF-κB gene expression in this cell line (Fig. 4b).

In the resistant HL-60/5FU cells, U-332 significantly decreased the mRNA level of c-Rel, RelA and NF-κB1 (1.7-, 2- and 4.6-fold, respectively), as compared with control (Fig. 5a). BGD down-regulated the expression of c-Rel, RelB and NF-κB1 while did not influence RelA and NF-κB2 in these cells (Fig. 5b).

Activity of NF-κB subunits
To determine the activity of NF-κB family members in HL-60 and HL60/5FU cell lines, the ELISA-based
method was used. Cancer cell lysates were prepared after 24 h exposure of cells to analog U-332 or BGD (at IC50 concentration each).

Consistent with the enhanced gene expression, the activity of cRel, RelA and NF-κB1 subunits was significantly up-regulated in HL-60/5FU cells in comparison with the effect observed in HL-60 cells (Fig. 6a). Incubation of HL-60 cells with U-332 drastically reduced the activity of c-Rel, while BGD did not influence any of NF-κB subunits (Fig. 6b). In the resistant cell line, U-332 potently reduced activity of c-Rel, RelA and NF-κB1, while BGD exerted the strongest effect on c-Rel, RelB and NF-κB1 subunits (Fig. 6c).

Discussion
Chemotherapeutic drugs are meant to kill disseminated cancer cells and prevent metastasis but many cancers develop resistance during treatment [36]. Activation of NF-κB or/and overexpression of ABC transmembrane proteins play a major role in the resistance of tumor cells to chemotherapy [2–4]. Many chemotherapeutic agents, including 5-FU, doxorubicin, etoposide or cisplatin have been reported to activate NF-κB and to up-regulate expression of ABC transporters [37–40]. In several cancer cell lines the inhibition of either NF-κB or ABC transporter activity increased intracellular accumulation of chemotherapeutic drugs [41–43]. For example imatinib, a known NF-κB inhibitor, reversed the acquired resistance to doxorubicin by down-regulating the level of ABCB1 through the inhibition of RelA (p65) activity [44]. Therefore, the combination of anticancer drugs with NF-κB and ABC transporter inhibitors can be considered an efficient approach to sensitize cancer cells to chemotherapy.

Table 2 Expression of NF-κB subunit genes involved in multidrug resistance in HL-60/5FU cells

| gene   | c-Rel | RelA | RelB | NF-κB1 | NF-κB2 |
|--------|-------|------|------|--------|--------|
| Control (HL-60) | 1.0 ± 0.02 | 1.0 ± 0.01 | 1.0 ± 0.08 | 1.0 ± 0.02 | 1.0 ± 0.02 |
| HL-60/5FU | 4.4 ± 0.2*** | 2.1 ± 0.1*** | 1.1 ± 0.04 | 2.9 ± 0.1*** | 1.2 ± 0.05 |

Data represent mean ± SEM of three independent experiments performed in triplicate. ***, p < 0.001

Fig. 3 The cytotoxic effect of U-332 (a) and BGD (b) on HL-60 and HL-60/5FU cells analyzed by MTT assay.
Various members of the NF-κB family are constitutively activated in many cancers via one of the two pathways: the canonical pathway involving RelA, NF-κB1 p50 and c-Rel and the non-canonical pathway engaging RelB and NF-κB2 p52. Generally, the canonical NF-κB pathway is known to mediate mostly inflammatory responses, while the non-canonical NF-κB and its components have been shown to have pro-tumorigenic effects in many cancer types. However, there is significant cross-regulation between the components of these pathways, emphasizing the importance of the NF-κB as a single, highly complex system with disease relevance in many types of cancer [45, 46].

In this report, we have shown that in HL-60/5FU resistant cells all 5 NF-κB subunit genes (RelA, RelB, NF-κB1, NF-κB2 and cRel) were significantly upregulated. By monitoring activation of both, the non-canonical and the canonical NF-κB pathway members we have demonstrated that in HL-60/5FU resistant cells U-332 was involved in the down-regulation of the canonical pathway (RelA, c-Rel and NF-κB1), while BGD inactivated some subunits of both pathways (c-Rel, RelB and NF-κB2). BGD is usually considered a universal inhibitor of both NF-κB pathways. Here, we have shown that in leukemic HL-60/5FU cells the levels of only three out of 5 NF-κB subunits were affected by BGD.

Conclusions
The important finding of the research presented here and in our previous papers [31, 33] was the identification of the novel uracil analog as a potent inhibitor of NF-κB and ABC1 transporter expression. The inactivation of NF-κB subunits was shown to correlate with the inhibition of ABC transporter activity which may lead to the increased accumulation of a drug in cancer cells.
Fig. 6 The activity of c-Rel, RelA, RelB, NF-κB1 (p100/p50), and NF-κB2 (p100/p52) in untreated HL-60 and HL-60/5FU (a); in HL-60 treated with U-332 or BGD (b); in HL-60/5FU treated with U-332 or BGD (c). Human ABC ELISA kits and extracts from cancer cells treated with U-332 or BGD (at IC50 concentration each) were used. As a positive control Raji nuclear extract was added. Data are expressed as mean ± SEM. Statistical significance was assessed using test t and one-way ANOVA and a post-hoc multiple comparison Student–Newman–Keuls test. **p < 0.01; ***p < 0.001 in comparison with control.
Abbreviations
S-FU: 5-Fluorouracil; ABC transporters: ATP-binding cassette transporters; ABCB1: P-glycoprotein; ABCB1: Multidrug resistance associate protein 1; ABCG2: Breast cancer resistance protein; AML: Acute myeloid leukemia; BGD: Bengamide; DMSO: Dimethyl sulfoxide; ECACC: European collection of cell cultures; FBS: Fetal bovine serum; HRP: Horseradish peroxidase; MDR: Multidrug resistance; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; PCR: Polymerase chain reaction; TNFRs: Tumor necrosis factor receptors

Acknowledgments
Not applicable.

Authors’ contributions
Conceptualization, A.D-P., T.J. and A.J.; Supervision, T.J. and A.J.; Writing original draft, A.D-P.; Reviewing and editing final version, T.J. and A.J. All authors read and approved the final version of the manuscript.

Funding
This research was funded by the grant Preludium NO DEC-2017/25/N/Z3/01039 from the National Science Center (NCN) to A.D-P. The funding source had no role in the design of this study and did not play any role during execution, analyses, interpretation of the data or decision to submit results.

Availability of data and materials
All data generated or analyzed during the present study are included in this published article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Biomolecular Chemistry, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland. 2Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Lodz, Poland.

Received: 9 October 2019 Accepted: 21 February 2020
Published online: 02 March 2020

References
1. Grove CS, Vassiliou GS. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech. 2014;7:941–51.
2. Sonneveld P, Suciu S, Weijermans P, Beksaç M, Neuwirtova R, Solfu G, Segeren CM. Cyclosporin a combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914). Br J Haematol. 2001;115:895–902.
3. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review, Taiwan. J Obstet Gynecol. 2009;48:239–44.
4. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The evolution of cancer? Dis Model Mech. 2014;7:941–948.
5. Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Peters GJ. S-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 2004;15:1025–32.
6. de la Cueva A, de Molina AR, Álvarez-Ayerza N, Ramos MA, Cebrián A, del Pulgar TG, Liscal JC. Combined S-FU and Chk1 inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One. 2013;8:e64496.
7. Focacetti C, Bruno A, Magnani E, Bartolini D, Principi E, Dallaglio K, Albinì a; effects of S-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One. 2015;10:e0115686.
8. Gao K, Liang Q, Zhao ZH, Li YF, Wang SF. Synergistic anticancer properties of docosahexaenoic acid and S-5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells. World J Gastroenterol. 2016;22:2971.
9. Duschinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J Am Chem Soc. 1957;79:4559–60.
10. Gardane A, Poovannala M, Vaidya A, Curcumin sensitizes quiescent leukemia cells to anti-mitotic drug S-fluorouracil by inducing proliferative responses in them. J Cancer Metastasis Treat. 2016;24:25–52.
11. Tian ZY, Du GJ, Xie SQ, Zhao J, Gao WY, Wang CJ. Synthesis and bioevaluation of 5-fluorouracil derivatives. Molecules. 2007;12:4550–7.
12. Castillo E, Navarro SA, Ramírez A, García MA, Grifín-Lisión C, Perán M, Marchal JA. S-Fluorouracil derivatives: a patent review (2012–2014). Expert Opin Ther Pat. 2015;25:1131–44.
13. Dlugosz A, Janecka A. ABC transporters in the development of multidrug resistance in cancer therapy. Curr Pharm Des. 2016;22:7405–16.
14. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr. 2001;33:453–8.
15. Dean M, Annillo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet. 2005;6:123–42.
16. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999;59:2532–5.
17. van der Kolk DM, de Vries EG, van Putten WL, Verdonck LF, Ossenkoppele GJ, Verhoef GE, Vellenga E. P-glycoprotein and multidrug resistance protein interactions in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res. 2000;6:3205–14.
18. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol. 2009;14:3–9.
19. Paszel-Jaworska A, Rubil B, Bednarczyk-Cwynar B, Zachutko L, Rybczynska M. Proapoptotic activity and ABC1-related multidrug resistance reduction ability of semisynthetic cleamicolic acid derivatives DOXOL and HIMOXL in human acute promyelocytic leukemia cells. Chem Biol Interact. 2015;242:1–12.
20. Katayama K, Noguchi K, Sugimoto Y. Regulations of P-glycoprotein/ABCB1 mRNA expression in MDR1 in human cancer cells. New J Sci. 2014;2014:10–1.
21. Zhou G, Kuo MT. NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biochem. 1997;272:15174–83.
22. Zhou G, Kuo MT. Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biochem. 1998;273:1387–94.
23. Ockinghaus A, Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1:a000394.
24. Schmitz ML, Baueerle PA. The p65 subunit is responsible for the strong transcriptional activation potential of NF-κB. EMBO J. 1991;10:3805–17.
25. Huang B, Yang XD, Lamb A, Chen LF. Posttranslational modifications of NF-κB: another layer of regulation for NF-κB signaling pathway. Cell Signal. 2010;22:1282–90.
26. Visekruna A, Volkov A, Steinhoff U. A key role for NF-κB transcription factor c-Rel in T-lymphocyte differentiation and effector functions. Clin Dev Immunol. 2012;2012:9.
27. Schmitz ML, Baueerle PA. The p65 subunit is responsible for the strong transcriptional activation potential of NF-κB. EMBO J. 1991;10:3805–17.
28. Wang B, Yang XD, Lamb A, Chen LF. Posttranslational modifications of NF-κB: another layer of regulation for NF-κB signaling pathway. Cell Signal. 2010;22:1282–90.
29. Visekruna A, Volkov A, Steinhoff U. A key role for NF-κB transcription factor c-Rel in T-lymphocyte differentiation and effector functions. Clin Dev Immunol. 2012;2012:9.
30. Coope HJ, Atkinson PG, Hulse B, Belich M, Janzen J, Holman MJ, Ley SC. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO Rep. 2002;2:857–85.
31. Fayh BN, Schliemann MG, Virudachalam S, Bold RJ. Inhibition of AKT abrogates chemotherapy-induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg. 2004;198:591–9.
32. Sakamoto K, Maeda S, Hikita Y, Nakagawa H, Hayakawa Y, Shibata W, Omata M. Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res. 2009;15:2248–58.
33. Dlugosz-Pokorska A, Drogosz J, Pięta M, Janecki T, Krajewskia U, Miroswski M, Janecka A. New uracil analogs with exocyclic methylidene group as potential anticancer agents. Anti Cancer Agents Med Chem. 2019. https://doi.org/10.2174/1871520619666191211104128.
34. Dlugosz-Pokorska A, Drogosz J, Pięta M, Janecki T, Krajewskia U, Miroswski M, Janecka A. New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line. Mol Biol Rep. 2019;46:5831–9.
35. White KN, Tenney K, Crews P. The Bengamides: a mini-review of natural sources, analogues, biological properties, biosynthetic origins, and future prospects. J Nat Prod. 2017;80:740–55.
33. Pięta M, Kędzia J, Kowalczyk D, Wojciechowski J, Wolf WM, Janecki T. Enantioselective synthesis of 5-methylidenedihydrouracils as potential anticancer agents. Tetrahedron. 2019;75:2495–505.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.
35. Winer J, Jung CKS, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase–polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:41–9.
36. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007;446:749–57.
37. Davoudi Z, Akbarzadeh A, Rahmatyamchi M, Movassaghpour AA, Alipour M, Nejati-Koshki K, Zarghami N. Molecular target therapy of AKT and NF-κB signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 cells. Asian Pac J Cancer Prev. 2014;15:4353–8.
38. Salvia AM, Cuvilid F, Coluzzi S, Niccolini R, Attolico I, Pascale SP, Ostuni A. Expression of some ATP-binding cassette transporters in acute myeloid leukemia. Hematol Rep. 2017;9:137–41.
39. Weldon CB, Burrow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS. NF-κB-mediated chemoresistance in breast cancer cells. Surgery. 2001;130:143–50.
40. Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, Miyagi Y. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells. Biochem Biophys Res Commun. 2012;423:667–71.
41. Zhang J, Lu M, Zhou F, Sun H, Hao G, Wu X, Wang G. Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20 (S)-ginsenoside Rh2. Drug Metab Disp. 2012;40:1900–8.
42. Xing Y, Wang ZH, Ma DH, Han Y. FTI720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1. J Dig Dis. 2014;15:246–59.
43. Huang C, Xu D, Xia Q, Wang P, Rong C, Su Y. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol. 2012;64:1741–50.
44. Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Platterer R. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One. 2013;8:e55509.
45. Ghosh S, Kari M. Missing pieces in the NF-kappaB puzzle. Cell. 2002;109:81–96.
46. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells. Oncogene. 2014;33(10):1297–305.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.